NCT02980042View on ClinicalTrials.gov

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab

A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells

DRUG

Rituximab

A chimeric monoclonal antibody against CD20.

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02980042 - Safety of Switching From Rituximab to Ocrelizumab in MS Patients | Biotech Hunter | Biotech Hunter